Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, F-75006 Paris, France.
Sickle Cell Referral Center, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France; INSERM U955 équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France; Laboratoire d'excellence GR-Ex, F75739 Paris, France; Université Paris-Est-Créteil (UPEC), Créteil, France.
Transfus Med Rev. 2019 Oct;33(4):225-230. doi: 10.1016/j.tmrv.2019.09.007. Epub 2019 Oct 18.
Transfusion-related hemolysis is classically the result of an interaction between antibodies produced by the recipient and blood group antigens carried by the donor red blood cells. This reaction may be life threatening, especially in sickle cell patients when they develop hyperhemolysis with concomitant accelerated clearance of their own red blood cells. The complement system is a key participant in the pathophysiology of post-transfusion hemolysis. Complement can trigger the hemolytic reaction, amplify the inflammatory response and increase tissue damage. Complement is activated by the classical pathway but may also be activated by the alternative pathway in sickle cell disease. The hemolysis-derived products permanently released by sickle cell patients with chronic hemolytic anemia may affect the potency of complement activation. All the observations in sickle cell patients as well as in vitro experiments and in vivo data in animal models support the conclusion that complement is key disease driver and a promising therapeutic target in the context of transfusion-related hemolysis and hyperhemolysis.
输血相关性溶血经典地是由受者产生的抗体与供者红细胞携带的血型抗原相互作用的结果。这种反应可能是危及生命的,特别是在镰状细胞病患者中,当他们发生伴有自身红细胞加速清除的高溶血性贫血时。补体系统是输血后溶血性疾病病理生理学的关键参与者。补体可以触发溶血性反应,放大炎症反应并增加组织损伤。补体通过经典途径激活,但在镰状细胞病中也可以通过替代途径激活。慢性溶血性贫血的镰状细胞病患者持续释放的溶血产物可能会影响补体激活的效力。所有在镰状细胞病患者中的观察、体外实验以及动物模型中的体内数据都支持这样的结论,即补体是输血相关性溶血和高溶血性贫血的关键疾病驱动因素和有前途的治疗靶点。